JTO Insights

Episode 13: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the October issue of the Journal of Thoracic Oncology.

Sai Yendamuri, MD, MBA, FACS, Director of the Thoracic Surgery Research Laboratory at Roswell Park Comprehensive Cancer Center in Buffalo, New York discusses their article Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction; and Mitsuhiro Isaka, MD, PhD, Deputy Chair of the Division of Thoracic Surgery at the Shizuoka Cancer Center in Shizuoka, Japan discusses their article Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L.

Recommended Reading:

1. Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction

https://www.jto.org/article/S1556-0864(26)00519-8/fulltext

2. Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L

https://www.jto.org/article/S1556-0864(26)00369-2/fulltext

3. JTO October 2026: Volume 21, Issue 10

https://www.jto.org/current

Podcast Hosts:

-Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

-Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Podcast Guests:

-Sai Yendamuri, MD, MBA, FACS, Chief Strategy Officer, SVP Business Development and Outreach, President and CEO, RPCI Oncology PC, Professor and Chair, Department of Thoracic Surgery, Director, Thoracic Surgery Research Laboratory, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

-Mitsuhiro Isaka, MD, PhD, Deputy Chief, Division of Thoracic Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan

In this episode of JTO Insights, recorded at the 2026 World Conference on Lung Cancer, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host the corresponding author of an article published in the JTO 20th Anniversary Series. Dr. Karen Reckamp, Professor of Medicine, Division of Medical Oncology at Cedars Sinai Medical Center, joins us to discuss their article, "The Evolution of Immunotherapy Revolution in Lung Cancer: a 20 Year Perspective."

Recommended Reading:

1. The Evolution of Immunotherapy Revolution in Lung Cancer: a 20 Year Perspective: https://www.jto.org/article/S1556-0864(26)00410-7/fulltext

2. JTO 20th Anniversary Series www.jto.org/content/20thAnniversarySeries

Podcast Hosts:

-Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

-Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Podcast Guest:

-Karen L. Reckamp, MD, MS, Department of Medicine, Division of Medical Oncology, Cedars Sinai Medical Center, Los Angeles, California

Episode 11: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the September issue of the Journal of Thoracic Oncology. Shun Lu, MD, PhD, Associate editor for the Journal of Thoracic Oncology; Director of Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine discusses their article SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China; and Hidetoshi Hayashi, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine discusses their article Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.

Recommended Reading:

-SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China G22

https://www.jto.org/article/S1556-0864(26)00166-8/fulltext

-Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report

https://www.jto.org/article/S1556-0864(26)00347-3/fulltext

-JTO Volume 21, Issue 9 - September 2026

https://www.jto.org/issue/S1556-0864(26)X2009-3

Podcast Hosts:

-Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

-Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Podcast Guests:

-Shun Lu, MD, PhD; Associate editor for the Journal of Thoracic Oncology; Director of Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

-Hidetoshi Hayashi, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, Osaka, Japan

Episode Summary

Episode 10: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host the corresponding author of an article published in the JTO 20th Anniversary Series. Dr. Jean-Louis Pujol, Professor at Montpellier School of Medicine of Montpellier University in France, joins us to discuss their article, "Lung cancer patient advocacy progress and new challenges since 2006".

Recommended Reading:

1. Lung cancer patient advocacy progress and new challenges since 2006 https://www.jto.org/article/S1556-0864(26)00345-X/fulltext

2. JTO 20th Anniversary Series https://www.jto.org/content/20thAnniversarySeries

Podcast Hosts:

-Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

-Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Podcast Guest:

-Jean-Louis Pujol, MD, PhD, Professor, Montpellier University, Montpellier School of Medicine, Montpellier, France

Episode 9: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John speak with authors of two articles published in the August issue of the Journal of Thoracic Oncology.

Michael J. Grant, MD, Assistant Professor of Medicine in the Section of Medical Oncology at Yale School of Medicine in New Haven, Connecticut, discusses “ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer.”

Christian Rolfo, MD, PhD, Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at The James Comprehensive Cancer Center, The Ohio State University, discusses “Molecular Profiling Across 80,000 Patients With Lung Cancer.”

Recommended Reading:

1. ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer

https://www.jto.org/article/S1556-0864(26)00161-9/fulltext

2. Molecular Profiling Across 80,000 Patients With Lung Cancer

https://www.jto.org/article/S1556-0864(26)00148-6/fulltext

3. August 2026, Volume 21, Issue 8

https://www.jto.org/issue/S1556-0864(26)X2007-X

Podcast Hosts:

-Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

-Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Podcast Guests:

-Michael J. Grant, MD, Assistant Professor of Medicine in the Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut

-Christian Rolfo, MD, PhD, Division Director of Medical Oncology, Associate Director for Early Phase Clinical Trials, The James Comprehensive Cancer Center, The Ohio State University, Ohio, United States

Episode Summary

Episode 8: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John highlight two articles published in the JTO 20th Anniversary Series. Dr. David Ryan of Royal Brompton & Harefield Hospitals, London, joins us to discuss their article, "Interventional Radiology and Thoracic Oncology: 20 Years of Innovation". Also featured in this episode is the article “Advances in Radiological Imaging for Thoracic Oncology: A 20-Year Perspective" by Drs. Jeremy Erasmus and Ioannis Vlahos.

Recommended Reading:

1. Interventional Radiology and Thoracic Oncology: 20 Years of Innovation: https://www.jto.org/article/S1556-0864(26)00343-6/fulltext

2. Advances in Radiological Imaging for Thoracic Oncology: A 20-Year Perspective: https://www.jto.org/article/S1556-0864(26)00016-X/fulltext

3. JTO 20th Anniversary Series: https://www.jto.org/content/20thAnniversarySeries

Podcast Hosts:

-Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

-Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Podcast Guest:

-David Ryan, MD, Royal Brompton Hospital, London, United Kingdom

Episode 7: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host Dr. Masahiro Torasawa, the corresponding author of "Tumor Inflammation–Associated Neurotoxicity Masquerading as Severe Immune Effector Cell–Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report" published in the Journal of Thoracic Oncology July issue.

Also featured in this episode is the article "TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors" by Di Federico et al.

Recommended Reading

1. Tumor Inflammation–Associated Neurotoxicity Masquerading as Severe Immune Effector Cell–Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report: https://www.jto.org/article/S1556-0864(26)00102-4/fulltext

2. TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors: https://www.jto.org/article/S1556-0864(26)00063-8/fulltext

3. This month’s issue: https://www.jto.org/issue/S1556-0864(26)X2006-8

Podcast Hosts:

-Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

-Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Podcast Guest:

-Masahiro Torasawa, MD, PhD, Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan

Episode 6: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host the corresponding author of an article published in the JTO 20th Anniversary Series. Dr. Emily Stone, a Conjoint Professor at the UNSW Sydney Faculty of Medicine and a consultant respiratory physician at St Vincent's Hospital, Sydney, joins us to discuss their article "Advances in Diagnosis - Pulmonology".

Recommended Reading

1. Advances in Diagnosis – Pulmonology: https://www.jto.org/article/S1556-0864(26)00101-2/fulltext

2. JTO 20th Anniversary Series: https://www.jto.org/content/20thAnniversarySeries

Podcast Hosts:

-Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

-Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Podcast Guest:

-Emily Stone, MBBS, PhD, FRACP, Conjoint Professor, Faculty of Medicine, UNSW; St Vincent’s Hospital, Sydney School of Clinical Medicine, UNSW, Sydney, Australia

Episode 5: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the Journal of Thoracic Oncology June issue. Dr. Natasha B. Leighl, Head of Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre, joins us to discuss their article "Identifying patients with high-risk stage I NSCLC using tumor-informed plasma ctDNA"; and Dr. Gabriella Sozzi, who leads the Experimental Oncology Department and Epigenomics & Biomarkers of Solid Tumors Unit at National Cancer Institute in Milan, Italy, joins to discuss their article, "Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose CT Lung Cancer Screening".

Recommended Reading:

1. Identifying patients with high-risk stage I NSCLC using tumor-informed plasma ctDNA: https://www.jto.org/article/S1556-0864(26)00098-5/fulltext

2. Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose CT Lung Cancer Screening: https://www.jto.org/article/S1556-0864(26)00067-5/fulltext

3. This month’s JTO issue: https://www.jto.org/issue/S1556-0864(26)X2004-4

Podcast Hosts:

-Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

-Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Podcast Guests:

-Gabriella Sozzi, PhD, Epigenomics & Biomarkers of Solid Tumors Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

-Natasha B. Leighl, MD, MMSc, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the JTO 20th Anniversary Series.

Dr. Stephen Lam, Director of the MDS-Rix Early Lung Cancer Detection and Translational Research Program at BC Cancer Research Institute, joins us to discuss their article, “A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening"; and Dr. Paul Van Schil, Consultant Thoracic Surgeon at Antwerp University Hospital, joins to discuss their article, "Journal of Thoracic Oncology 20th Anniversary Series - Surgery".

Recommended Reading:

1. JTO 20th Anniversary Series: https://www.jto.org/content/20thAnniversarySeries

2. A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening: https://www.jto.org/article/S1556-0864(25)02935-1/fulltext

3. Journal of Thoracic Oncology 20th Anniversary Series - Surgery: https://www.jto.org/article/S1556-0864(25)02938-7/fulltext

Podcast Hosts:

-Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

-Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Podcast Guests:

-Paul E. Van Schil, MD, PhD, Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium

-Stephen Lam, MD, FRCPC, BC Cancer Research Institute, Vancouver, British Columbia, Canada